« Return to News | CROs/Service Providers

Parexel Cuts 2009 Guidance, Shares Fall 40%

Tuesday, October 28, 2008 12:23 PM

Waltham, Mass.-based contract research organization Parexel reduced its 2009 fiscal year guidance, and share prices plunged more than 40% to $8.05 in late morning trading.

Citing slower than expected sales in September and a negative impact from foreign exchange rates, the company lowered its full-year consolidated revenue guidance to $1.1 to $1.3 billion, down from $1.22 to $1.25.

“We anticipated a slowdown during the summer months, and then expected an acceleration of activity in September as has been typical in the past. Ultimately, however, sales performance for the quarter turned out to be short of target,” said Parexel chairman and CEO Josef H. von Rickenbach in a company statement.

Parexel reported service revenues of $263 million for the first quarter of fiscal year 2009, a 26.4% increase compared with the same period prior year, but net income for the quarter was down to $13.6 million from $13.9 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.